Hemolytic Disease of the Fetus and Newborn (Erythroblastosis Fetalis)

Hemolytic disease of the fetus and newborn (HDFN), historically called erythroblastosis fetalis, is hemolysis of fetal and neonatal red cells caused by maternal IgG alloantibodies that cross the placenta and bind fetal red-cell antigens inherited from the father. The classic and most severe form involves anti-D in an RhD-negative mother carrying an RhD-positive fetus.

Definition

Hemolytic disease of the fetus and newborn is alloimmune hemolysis in which maternal IgG antibodies against fetal red-cell antigens cross the placenta and destroy fetal and neonatal red cells, producing fetal anemia and neonatal hyperbilirubinemia.

Scope

The entry covers the alloimmune mechanism of HDFN, the antigen systems involved (RhD and other Rh antigens, ABO, and others), the resulting fetal and neonatal hemolysis with its laboratory and clinical hallmarks, and the principle of prevention through anti-D prophylaxis. It is a reference and classification topic and does not provide management or dosing instructions.

Core questions

• Which red-cell antigen system is the maternal alloantibody directed against (RhD, other Rh, ABO, or another)?
• How does transplacental passage of maternal IgG produce fetal anemia and neonatal jaundice?
• How does maternal alloimmunization arise, and how is RhD sensitization prevented?

Key concepts

• Maternal alloimmunization
• Transplacental IgG transfer
• RhD incompatibility
• ABO incompatibility
• Fetal anemia and hydrops fetalis
• Neonatal hyperbilirubinemia
• Anti-D immunoglobulin prophylaxis
• Direct antiglobulin test in the newborn

Mechanisms

When a mother lacks a red-cell antigen that the fetus has inherited from the father, exposure to fetal red cells (for example at delivery or after fetomaternal hemorrhage) can prompt maternal alloantibody formation (tormey-2019). In a subsequent sensitized pregnancy, maternal IgG crosses the placenta, coats fetal red cells, and drives their destruction, causing fetal anemia that in severe cases progresses to high-output cardiac failure and hydrops fetalis; after birth the loss of placental bilirubin clearance leads to neonatal hyperbilirubinemia (delaney-2015). The neonatal direct antiglobulin test is typically positive, and hemolytic markers reflect ongoing red-cell destruction (barcellini-2015). RhD-mediated disease is classically the most severe, while ABO incompatibility tends to be milder (delaney-2015).

Clinical relevance

HDFN is a defining example of alloimmune hemolysis and of how maternal antibody screening and anti-D prophylaxis transformed a once-common cause of neonatal death into a largely preventable condition. This entry describes the mechanism and classification for reference and educational purposes and is not a basis for individual obstetric or neonatal decisions.

Epidemiology

The incidence of severe RhD HDFN has fallen markedly in settings where antenatal and postnatal anti-D immunoglobulin prophylaxis and maternal antibody screening are routine; alloantibodies other than anti-D and ABO incompatibility now account for a relatively larger share of residual cases (delaney-2015, tormey-2019).

Evidence & guidelines

Educational reviews summarize the alloimmune basis, antenatal monitoring, and the role of anti-D prophylaxis in HDFN (delaney-2015) and the broader biology of red-cell alloimmunization (tormey-2019); these are descriptive references rather than prescriptive protocols.

Seminal works

• delaney-2015
• tormey-2019

Frequently asked questions

Why is RhD incompatibility the classic cause of hemolytic disease of the newborn?

Anti-D is a strongly immunogenic IgG antibody that crosses the placenta efficiently and causes severe fetal red-cell destruction, which is why RhD-mediated disease was historically the most dangerous form before anti-D prophylaxis became routine.

How is RhD hemolytic disease prevented?

Administration of anti-D immunoglobulin to RhD-negative mothers reduces maternal alloimmunization against the RhD antigen; this entry describes the principle for reference only and not as dosing guidance.